클라임 바이오(CLYM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $14.32 (+1.85%), 시가총액 $0.60B, 52주 최저~최고 $1.17 ~ $12.22.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephro
클라임 바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
클라임 바이오의 현재 주가는 $14.32 (+1.85%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
클라임 바이오의 시가총액은 약 $0.60B입니다.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate